个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Adjuvant osimertinib in patients with completely resected, stage IB-IIIB NSCLC with uncommon EGFR mutations (ADMIN): Clinical characteristics, genomic profile and molecular residual disease

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Liu, C.[1] * ; Han, Y.[2] ; Leng, X.[2] ; Yue, D.[3] ; Zhao, G.[4] ; Cheng, C.[5] ; Li, G.[6] ; Liang, N.[7] ; Zhao, J.[8] ; Liu, S.[9] ; Huang, W.[10] ; Wang, J.[10] ; Liu, L.[11,12] ;
机构： [1]Sichuan Univ, West China Hosp, West China Sch Med, Dept Thorac Surg, Chengdu, Peoples R China [2]UESTC, Dept Thorac Surg, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp,Sch Med, Chengdu, Peoples R China [3]TMUCIH Tianjin Med Univ Canc Inst & Hosp, Lung Canc Dept, Tianjin, Peoples R China [4]Ningbo 2 Hosp, Dept Thorac Surg, Ningbo, Peoples R China [5]Sun Yat Sen Univ, Dept Thorac Surg, First Affiliated Hosp 1, Guangzhou, Peoples R China [6]Yunnan Canc Hosp, Dept Thorac Surg, Kunming, Yunnan, Peoples R China [7]Beijing Xiehe Hosp, PUMCH Peking Union Med Coll Hosp, Dept Thorac Surg, Dongdan Campus, Beijing, Peoples R China [8]Soochow Univ, Affiliated Hosp 1, Dept Thorac Surg, Suzhou, Peoples R China [9]Fujian Prov Canc Hosp, Dept Thorac Surg, Fuzhou, Peoples R China [10]AstraZeneca, Dept Med Affairs, Shanghai, Peoples R China [11]Sichuan Univ, Dept Thorac Surg, West China Hosp, Chengdu, Peoples R China [12]Sichuan Univ, Inst Thorac Oncol, West China Hosp, Chengdu, Peoples R China
出处：
DOI： 10.1016/j.annonc.2024.10.624
ISSN：
基金：
AstraZeneca, China
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Sichuan Univ, West China Hosp, West China Sch Med, Dept Thorac Surg, Chengdu, Peoples R China
推荐引用方式(GB/T 7714)：
Liu C.,Han Y.,Leng X.,et al.Adjuvant osimertinib in patients with completely resected, stage IB-IIIB NSCLC with uncommon EGFR mutations (ADMIN): Clinical characteristics, genomic profile and molecular residual disease[J].ANNALS OF ONCOLOGY.2024,35:S1617-S1617.doi:10.1016/j.annonc.2024.10.624.
APA：
Liu, C.,Han, Y.,Leng, X.,Yue, D.,Zhao, G....&Liu, L..(2024).Adjuvant osimertinib in patients with completely resected, stage IB-IIIB NSCLC with uncommon EGFR mutations (ADMIN): Clinical characteristics, genomic profile and molecular residual disease.ANNALS OF ONCOLOGY,35,
MLA：
Liu, C.,et al."Adjuvant osimertinib in patients with completely resected, stage IB-IIIB NSCLC with uncommon EGFR mutations (ADMIN): Clinical characteristics, genomic profile and molecular residual disease".ANNALS OF ONCOLOGY 35.(2024):S1617-S1617

资源点击量：54674 今日访问量：0 总访问量：4645 更新日期：2025-03-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号